<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00203151</url>
  </required_header>
  <id_info>
    <org_study_id>TV-4710/201</org_study_id>
    <nct_id>NCT00203151</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Tolerability, Safety and Effectiveness of Edratide in the Treatment of Lupus</brief_title>
  <acronym>PRELUDE</acronym>
  <official_title>A Multi-National, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Parallel Group Study to Assess the Efficacy, Tolerability and Safety of Edratide for Subcutaneous Injection in Systemic Lupus Erythematosus (SLE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceutical Industries</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <brief_summary>
    <textblock>
      It is thought that Edratide may be able to reduce the symptoms of SLE.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    TV-4710/201 did not meet its primary endpoints in patients with SLE
  </why_stopped>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of Disease Activity Score</measure>
    <time_frame>30 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">340</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>edratide</intervention_name>
    <description>0.5 mg, 1.0 mg, 2.5 mg injection once weekly</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Willing and able to give written informed consent

          2. Between the ages of 18 and 65 years (inclusive)

          3. Fulfilled at least 4 ACR classification criteria

          4. SLE patients with moderate, active disease

          5. Subjects on stable dose of SLE medications for at least 4 weeks before randomization.

          6. Women of child-bearing potential must practice a medically acceptable method of
             contraception..

          7. Must understand the requirements of the study and agree to comply with the study
             protocol.

        Exclusion Criteria:

          1. Any condition which the investigator feels may interfere with participation in the
             study.

          2. Subjects having a history of chronic infection

          3. Subjects with a history of immunodeficiency syndrome or malignancy,

          4. Subjects who received any investigational medication (including DHEA) within 3 months
             prior to randomization,

          5. Subjects treated with any cytotoxic agents in the 3 months prior to randomization.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan Goldsatub, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Teva Pharmaceutical Industries</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>April 8, 2011</last_update_submitted>
  <last_update_submitted_qc>April 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 12, 2011</last_update_posted>
  <responsible_party>
    <name_title>Rivka Kreitman, Ph.D., Vice President, Innovative Research &amp; Development</name_title>
    <organization>Teva Neuroscience</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

